WallStSmart

Kalvista Pharmaceuticals Inc (KALV)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kalvista Pharmaceuticals Inc generates 15329% more annual revenue ($114.48M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -118.7%. KALV earns a higher WallStSmart Score of 28/100 (F).

KALV

Avoid

28

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -3.71

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KALV2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
30.7%10/10

Revenue surging 30.7% year-over-year

Debt/EquityHealth
-104.8310/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

KALV4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.44B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-190.2%2/10

ROE of -190.2% — below average capital efficiency

Altman Z-ScoreHealth
-3.712/10

Distress zone — elevated risk

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : KALV

The strongest argument for KALV centers on Revenue Growth, Debt/Equity. Revenue growth of 30.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : KALV

The primary concerns for KALV are EPS Growth, Market Cap, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

KALV profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

KALV is growing revenue faster at 30.7% — sustainability is the question.

KALV generates stronger free cash flow (45M), providing more financial flexibility.

Bottom Line

KALV scores higher overall (28/100 vs 24/100) and 30.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kalvista Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?